Discover
SLS
SELLAS Life Sciences Group, Inc.
11.93
2 x 8.31
2 x 14.48
bid
ask
+
0.28
2.40%
2 @ 08:45 AM
11.79 -0.14 (1.17%)
| Ytd | 216.45% | |
| 1y | 496.50% |
11.48
day range
12.14
1.39
52 week range
15.88
| Open | 11.63 | Prev Close | 11.65 | Low | 11.48 | High | 12.14 | Mkt Cap | 2.41B |
| Vol | 4.02M | Avg Vol | 6.47M | EPS | -0.21 | P/E | N/A | Forward P/E | -119.30 |
| Beta | 2.56 | Short Ratio | 8.57 | Inst. Own | 36.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 12.44 | 200-d Avg | 8.05 | 1yr Est | 32.50 |
| Income Statement | |||
| Operating Expenses | 10.63M | ||
| Research and Development Expense | 6.27M | ||
| Selling, General and Administrative Expense | 4.36M | ||
| Operating Income | -10.63M | ||
| Net Income | -9.60M | ||
| Net Income Common Stock | -9.60M | ||
| Net Income Common Stock (USD) | -9.60M | ||
| Consolidated Income | -9.60M | ||
| Earnings per Basic Share | -0.05 | ||
| Earnings per Basic Share (USD) | -0.05 | ||
| Earnings per Diluted Share | -0.05 | ||
| Earning Before Interest & Taxes (EBIT) | -9.60M | ||
| Earning Before Interest & Taxes (USD) | -9.60M | ||
| Weighted Average Shares | 189.18M | ||
| Weighted Average Shares Diluted | 189.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 138.44M | ||
| Cash and Equivalents (USD) | 138.44M | ||
| Current Assets | 142.51M | ||
| Property, Plant & Equipment Net | 710.00K | ||
| Total Assets | 145.38M | ||
| Debt Current | 580.00K | ||
| Total Debt | 737.00K | ||
| Current Liabilities | 7.57M | ||
| Debt Non-Current | 157.00K | ||
| Total Liabilities | 7.73M | ||
| Accumulated Retained Earnings (Deficit) | -293.00M | ||
| Shareholders Equity | 137.66M | ||
| Shareholders Equity (USD) | 137.66M | ||
| Assets Non-Current | 2.88M | ||
| Total Debt (USD) | 737.00K | ||
| Goodwill and Intangible Assets | 1.91M | ||
| Liabilities Non-Current | 157.00K | ||
| Trade and Non-Trade Payables | 3.09M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 154.00K | ||
| Net Cash Flow from Financing | 38.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 31.25M | ||
| Issuance (Purchase) of Equity Shares | 38.83M | ||
| Net Cash Flow from Operations | -7.59M | ||
| Share Based Compensation | 1.01M | ||